Shopping Cart
- Remove All
Your shopping cart is currently empty
MK2-IN-3 hydrate
Catalog No. T12058Cas No. 1186648-22-5
Alias MK-2 Inhibitor III
MK2-IN-3 hydrate (MK-2 Inhibitor III) is an orally active, selective, and ATP-competitive inhibitor of MAPKAP-K2 (MK-2) (IC50 of 0.85 nM)
MK2-IN-3 hydrate
Catalog No. T12058Alias MK-2 Inhibitor IIICas No. 1186648-22-5
MK2-IN-3 hydrate (MK-2 Inhibitor III) is an orally active, selective, and ATP-competitive inhibitor of MAPKAP-K2 (MK-2) (IC50 of 0.85 nM)
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $48 | In Stock | |
| 5 mg | $97 | In Stock | |
| 10 mg | $157 | In Stock | |
| 25 mg | $316 | In Stock | |
| 50 mg | $461 | In Stock | |
| 100 mg | $648 | In Stock | |
| 500 mg | $1,290 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $118 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "MK2-IN-3 hydrate"
Lidocaine hydrochloride
Cited
Xyloneural, Lignocaine hydrochloride, Lidothesin, Lidocaine HCL
T114473-78-9
Lidocaine hydrochloride (Lignocaine hydrochloride) is a local anesthetic and cardiac depressant used as an antiarrhythmic agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
- $45
Size
QTY
CitedTBHQ
Cited
tert-Butylhydroquinone
T53641948-33-0
TBHQ (tert-Butylhydroquinone) is an antioxidant that induces an antioxidant response through the redox-sensitive transcription factor Nrf2.
- $41
Size
QTY
Citedsodium lauroyl-α-hydroxyethyl sulfonate
T7283112714-99-5
Sodium houttuyfonate is anti-pseudomonas agents, inhibits virulence-related motility of Pseudomonas.
- $53
Size
QTY
Lidocaine
Xylocaine, Lignocaine, Alphacaine
T0468137-58-6
Lidocaine (Alphacaine) is an amide local anesthetic with anti-inflammatory properties in vitro and in vivo. It has this functions perhaps due to an attenuation of intracellular adhesion molecule-1 (ICAM-1), pro-inflammatory cytokines, and reduction of neutrophils influx.
- $45
Size
QTY
Tauroursodeoxycholate Cited
Ursodeoxycholyltaurine, UR 906, TUDCA, Tauroursodeoxycholic Acid, Taurolite
T253214605-22-2
Tauroursodeoxycholate (UR 906), also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.
- $50
Size
QTY
CitedAstragaloside IV Cited
AST-IV, AS-IV
T297384687-43-4
Astragaloside IV (AS-IV), an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells. Astragaloside IV is a bioactive saponin first isolated from the dried plant roots of the genus Astragalus, which is used in traditional Chinese medicine.1 It dose-dependently inhibits human adenovirus type 3 (HAdV-3) in A549 cells (IC50 = 23 μM; LC50 = 865 μM).It inhibits replication of HAdV-3 and decreases HAdV-3-induced apoptosis. It has diverse protective effects for the cardiovascular, immune, digestive, and nervous systems. In particular, it reduces myocardial infarct size in dogs when administered prior to coronary ligation and reduces reperfusion arrhythmias in isolated rat hearts.
- $32
Size
QTY
CitedNotoginsenoside R1
Sanqi glucoside R1, Sanchinoside R1
T296180418-24-2
Notoginsenoside R1 (Sanchinoside R1) has been shown to exhibit antioxidant, antiapoptotic, anti-inflammatory, and immune-stimulatory properties.
- $63
Size
QTY
Honokiol Cited
NSC 293100
T300135354-74-6
Honokiol (NSC-293100) is the active principle of magnolia extract. It inhibits the activation of Akt and enhances the phosphorylation of ERK1/ERK2.
- $50
Size
QTY
CitedVemurafenib Cited
RO5185426, RG7204, PLX4032
T2382918504-65-1
Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently. Vemurafenib exhibits antitumor activity and is used for the treatment of BRAF V600E mutation-positive melanoma.
- $50
Size
QTY
CitedRo-3306 Cited
T2356872573-93-8
RO-3306 is a selectivity ATP-competitive CDK1 inhibitor (Ki: 20 nM). The selectivity of RO-3306 for CDK1 is >15-fold higher than a diverse panel of human kinases.
- $32
Size
QTY
CitedSelumetinib Cited
AZD6244, ARRY-142886
T6218606143-52-6
Selumetinib (AZD6244) is a MEK1/2 inhibitor that inhibits MEK1 (IC50=14 nM) with potent selectivity and is non-ATP-competitive. Selumetinib has antitumor activity and is used for the treatment of neurofibromatosis type 1 (NF1).
- $47
Size
QTY
Cited
Select Batch
Purity:99.14%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | MK2-IN-3 hydrate (MK-2 Inhibitor III) is an orally active, selective, and ATP-competitive inhibitor of MAPKAP-K2 (MK-2) (IC50 of 0.85 nM) |
| Targets&IC50 | MK2:0.85 nM, MK3:0.21 μM, MNK1:5.7 μM, ERK2:3.44 μM, MK5:0.081 μM |
| In vitro | MK-2 Inhibitor III suppresses TNFα production (IC50 of 4.4 μM, in U397 cells)[1]. |
| Alias | MK-2 Inhibitor III |
| Molecular Weight | 358.39 |
| Formula | C21H18N4O2 |
| Cas No. | 1186648-22-5 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 65 mg/mL (181.37 mM)  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy MK2-IN-3 hydrate | purchase MK2-IN-3 hydrate | MK2-IN-3 hydrate cost | order MK2-IN-3 hydrate | MK2-IN-3 hydrate chemical structure | MK2-IN-3 hydrate in vitro | MK2-IN-3 hydrate formula | MK2-IN-3 hydrate molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.